Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.168 EUR
−238.55 M EUR
682.41 M EUR
87.40 M
About Myriad Genetics, Inc.
Sector
Industry
CEO
Paul J. Diaz
Website
Headquarters
Salt Lake City
Founded
1991
FIGI
BBG000KNHH28
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on MUN exchange MYRIAD GENETICS DL-,01 stocks are traded under the ticker MYD.
We've gathered analysts' opinions on MYRIAD GENETICS DL-,01 future price: according to them, MYD price has a max estimate of 32.65 EUR and a min estimate of 13.06 EUR. Watch MYD chart and read a more detailed MYRIAD GENETICS DL-,01 stock forecast: see what analysts think of MYRIAD GENETICS DL-,01 and suggest that you do with its stocks.
Yes, you can track MYRIAD GENETICS DL-,01 financials in yearly and quarterly reports right on TradingView.
MYRIAD GENETICS DL-,01 is going to release the next earnings report on Mar 4, 2025. Keep track of upcoming events with our Earnings Calendar.
MYD earnings for the last quarter are 0.05 EUR per share, whereas the estimation was 0.02 EUR resulting in a 220.15% surprise. The estimated earnings for the next quarter are 0.03 EUR per share. See more details about MYRIAD GENETICS DL-,01 earnings.
MYRIAD GENETICS DL-,01 revenue for the last quarter amounts to 191.57 M EUR, despite the estimated figure of 189.29 M EUR. In the next quarter, revenue is expected to reach 202.19 M EUR.
MYD net income for the last quarter is −19.85 M EUR, while the quarter before that showed −34.26 M EUR of net income which accounts for 42.07% change. Track more MYRIAD GENETICS DL-,01 financial stats to get the full picture.
No, MYD doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 15, 2024, the company has 2.70 K employees. See our rating of the largest employees — is MYRIAD GENETICS DL-,01 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MYRIAD GENETICS DL-,01 EBITDA is −37.63 M EUR, and current EBITDA margin is −9.48%. See more stats in MYRIAD GENETICS DL-,01 financial statements.
Like other stocks, MYD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MYRIAD GENETICS DL-,01 stock right from TradingView charts — choose your broker and connect to your account.